Catalogue: Resources for COVID-19 and influenza vaccine development
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
List view / Grid view
A panel of SARS-CoV-2 reagents (e.g. antigens, antibodies, and kits) and influenza antigens have been developed to support the development of vaccines.
Scientists say COVID-19 may activate tuberculosis infection, but stem cell-mediated defence mechanisms could be targeted to develop vaccines.
Scientists have found differences in 206 genes between the GRCh38 (hg38) and GRCh37 (hg19) human reference genomes.
For the first time, scientists have found evidence that polymerase theta can write RNA segments back into DNA.
Researchers have shown that the SARS-CoV-2 PLpro cuts human proteins so could potentially cause a range of COVID-19 symptoms.
Researchers have created an X-ray scanning machine that shows the shape of an object and its molecular composition.
Complete solutions for neurological disease research and discovery - helping you to better understand diseases to improve patient outcomes.
Analysis of one million SARS-CoV-2 genome sequences has revealed a new variant named T478K, spreading mostly in Mexico.
We discuss how liquid handling automation supports drug discovery workflows & highlight opportunities to improve the efficiency and quality of these.
Scientists have created a RT-ddPCR assay to analyse both the non-coding and coding RNA regions of SARS-CoV-2.
Learn about a practical, high-throughput method for validating the target-specificity of antibodies for the application of western blot.
A new non-invasive microscopic fluorescence imaging method has been developed to reveal details of the brain in animal models of various diseases.
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
Researchers have explored the interaction between SARS-CoV-2 RNA and the host cell, uncovering possible targets to prevent viral replication.
The WHO and Swiss Confederation are set to launch a BioHub Facility, intended to facilitate the sharing of pathogens globally.